Aims Despite advances in the treatment of acute coronary syndromes based on randomized trial data and published guidelines, the extent to which such treatments are applied in practice remains uncertain. Data from clinical trials derive from selected geographical areas and in highly selected populations of patients, and hence may not reflect the overall population. The aim of the study was to investigate variations in hospital management and outcome using unselected data collected in the prospective Global Registry of Acute Coronary Events (GRACE).
Introduction
Acute coronary syndromes encompass myocardial infarction, non-Q-wave myocardial infarction, and unstable angina, all of which are common causes of emergency hospital admission and a major cause of morbidity and mortality worldwide [1] [2] [3] . According to recent figures, in the United States more than 12 million people have coronary heart disease and more than 1 million experience an acute myocardial infarction or fatal coronary heart disease each year, resulting in over 466 000 deaths attributed to coronary heart disease [4] . The European Network for Acute Coronary Treatment (ENACT) survey [2] , conducted in 29 countries across Europe, has found that unstable angina is a more frequent cause of hospitalization than myocardial infarction (ratio 1·2:1). Although some studies, such as the WHO Multinational Monitoring of Trends and Determinants in Cardiovascular Disease (MONICA) Project [5] , show a decreasing trend in age-adjusted mortality due to coronary events, acute coronary syndromes are the most prevalent cause of death in patients hospitalized for medical conditions. In the context of clinical trials, substantial variation in treatment and outcome have been observed, but the extent to which such variations exist in unselected populations is unclear [6] . Patients with an acute coronary syndrome who present with ST-segment elevation myocardial infarction (STEMI) are a distinct component of the syndrome, and treatment aims to restore perfusion using fibrinolysis or primary percutaneous coronary intervention [2, 7, 8] . However, non-ST-segment elevation myocardial infarction (non-STEMI) and unstable angina are more heterogeneous in their presentation and may be poorly characterized in clinical practice, leading to greater variation in diagnosis and treatment [9, 10] . Unstable angina in particular has a wide range of clinical manifestations, resulting in a variable prognosis [11] . This variation may be explained by the use of different definitions for unstable angina and non-STEMI [10] , by differences in the characteristics of presenting patients, and by geographical practice variation [12] , which can itself be influenced by factors such as the incidence of coronary heart disease in the local population, the type of resources available, and physicians' perceptions of existing therapies [12] . The need exists, therefore, for robust data from unselected populations and with prospectively defined disease definitions.
Over the past decade, based upon increased understanding of the underlying pathophysiology, advances have been made in therapeutic interventions and new drugs for the treatment of acute coronary syndromes [13] . Multinational and local guidelines for the use of such treatments are based upon data from randomized clinical trials that are conducted in restricted geographical locations and in highly selected populations of patients [2] . The extent to which trial-based evidence is applied in wider unselected populations is uncertain. In addition, it is unclear what effect treatments have on short-and longer term outcomes in the broad spectrum of patients with extended age ranges and co-morbidity, as seen in clinical practice. The multinational GRACE project was established to provide robust, real-life, population-based treatment data for patients with an acute coronary syndrome. It is hoped that such reference data will provide the basis for improved evidence-based management of acute coronary syndromes. This report presents data from the first 11 543 patients from GRACE. It investigates whether the use of various interventions and medications are influenced by hospital type and by geographical location, and it relates these findings to hospital outcome.
Methods
GRACE is designed to reflect an unbiased and statistically robust population of well-characterized patients with acute coronary syndromes, irrespective of geographical location. Full details of the GRACE rationale and methodology have been previously published [1] , but are summarized below.
Ninety five hospitals in 14 countries in Europe, North and South America, Australia and New Zealand are participating in GRACE. Following a similar approach to that adopted in the MONICA study [5] , hospitals are organized into population-based clusters that reflect the population characteristics of that region. Participating hospitals reflected the full spectrum of hospital types and facilities, ranging from community institutions to large tertiary facilities. The aim is to establish a representative rather than selective study population.
Patient identification
Patients are identified using either prospective (warm pursuit) or retrospective (cold pursuit) methodology, and each site follows either the prospective or retrospective approach. In hospitals using warm pursuit, eligible patients are identified using their index admission and medical records, whereas in hospitals using cold pursuit hospital discharge listings are reviewed [1] . The majority of study centres use warm pursuit. Patients are assessed and details recorded about hospital management and outcome. Patients are followed-up at 6 months to determine longer term outcomes and subsequent use of medications. Hospitals obtained approval from their local hospital ethics committee or institutional review board for the conduct of the study in accordance with local guidelines. Signed informed consent for follow-up contact is obtained from the patients at enrolment.
To be included in GRACE patients had to have an acute coronary syndrome as a presumptive diagnosis (see Appendix 2), be at least 18 years old, and alive at the time of hospital presentation. Patients were excluded from the study if the qualifying acute coronary syndrome was precipitated or accompanied by a confounding co-morbidity such as a road accident, trauma or operation, or if the patient was already hospitalized when they developed symptoms of an acute coronary syndrome. The community-based approach meant that patients who lived outside the geographical catchment area were also excluded. Patients transferred into or out of a registry hospital were enrolled regardless of the time spent at the transferring hospital. Patients could be re-enrolled in GRACE provided there was a 6-month interval since the previous enrolment, and in such instances a new patient number was allocated. Patients hospitalized for less than 1 day who died due to a confirmed acute coronary syndrome were included (Appendix 2).
Data collection
A standardized case record form was piloted, validated and used to collect information on patient demographic characteristics, presenting symptoms, medical history, patient management, treatment and outcome. Data were also collected 6 months after discharge to ascertain longer term mortality, development of clinical events, and use of various treatments following hospital discharge.
Quality control measures
All individuals involved in data collection received training in completing the core record form and the extraction of data from medical records. Computerized audit checks were performed, and a randomized audit of all sites is being conducted over a 3-year cycle. Data are entered into the database at the core data-management facility (Premier Research, Philadelphia PA) following review for completeness and outliers. Data are scanned directly into the electronic database and then checked manually. Cleaned data sets are forwarded to the coordinating centre (Center for Outcomes Research, University of Massachusetts, MA) for analysis. Data collection began in April 1999, with the aim of collecting data on approximately 10 000 patients hospitalized per annum with an acute coronary syndrome.
Statistical methods
Statistical analysis was based on 11 543 patients enrolled in GRACE. The analysis focused on the following three groups: STEMI, non-STEMI, and unstable angina. A chi-square test was used for categorical data and t-test for continuous variables. All tests were two-sided and considered significant at c0·05. The statistical analysis was performed using SAS software package (version 8.1, SAS Institute, Cary, N.C.).
Results

Demographics
The data presented in this paper are based on the first 11 543 patients with acute coronary syndromes recruited in 95 hospitals in 14 countries between April 1999 and 31 December 2000. The admission diagnoses versus final diagnoses are illustrated in Fig. 1 . At presentation to hospital 4999 (44%) were diagnosed with unstable angina and 4100 (36%) with myocardial infarction, 957 (9%) were admitted to rule out a myocardial infarction, 745 (7%) had chest pain, 381 (3%) were hospitalized with 'other cardiac' and 125 (1%) with 'non-cardiac' diagnoses. Of those with an admission diagnosis of unstable angina (4999 patients) 1190 (24%) progressed to non-STEMI and 285 (6%) to STEMI. Of those with an admission diagnosis of myocardial infarction (4100 patients) 845 (21%) evolved to non-STEMI and 2808 (69%) to STEMI. Three hundred and sixty (38%) patients with a 'rule-out' myocardial infarction diagnosis at presentation developed non-STEMI, 125 (13%) STEMI and 345 (36%) unstable angina. Two hundred and seventeen (29%) patients with unspecified chest pain at admission developed non-STEMI, 80 (11%) STEMI and 289 (39%) unstable angina. One hundred and 
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fifty-five (41%) with 'other cardiac' diagnosis at presentation progressed to non-STEMI, 57 (15%) STEMI, and 84 (22%) unstable angina. Finally 67 (54%) patients with other non-cardiac diagnoses at admission developed non-STEMI, 23 (18%) STEMI, and 18 (14%) unstable angina. As of December 2000, 6-month follow-up was completed in 6641 (70%) of eligible patients. The demographic details and baseline characteristics are presented in Table 1 . The mean age in the STEMI, non-STEMI, and unstable angina groups was similar (mean 65 13 years). The majority of patients were male (66%), and 32% had a history of prior myocardial infarction. When analysed by hospital type, significantly more patients with a prior myocardial infarction presented to teaching than non-teaching hospitals (34 vs 30%; P<0·0001) and to sites with access to a cardiac catheterization laboratory than to those without (33 vs 30%; P<0·0005). A similar trend was observed in patients who had undergone a previous cardiac catheterization, with significantly more patients being admitted to teaching than non-teaching hospitals (34 vs 25%; P<0·0001) and to hospitals with cardiac catheterization facilities compared to those without (36 vs 16%; P<0·0001).
Pharmacological and interventional treatments
The use of pharmacological and interventional therapies during hospitalization ( Fig. 2 ) and following discharge ( Fig. 3 ) was analysed by hospital type (teaching vs non-teaching) and by presence or absence of on-site cardiac catheterization facilities. Use of aspirin was widely adopted, with 91% of patients receiving this treatment. The use of percutaneous coronary intervention, glycoprotein IIb/IIIa inhibitors and calciumchannel blockers was statistically higher (P<0·01) in teaching hospitals and hospitals with on-site catheterization facilities compared with non-teaching hospitals and those without catheterization facilities. Conversely, the use of low-molecular-weight heparin was statistically lower (P<0·0001) in teaching hospitals and those with a catheterization laboratory.
The use of angiotensin-converting enzyme inhibitors at discharge was consistent between teaching and nonteaching hospitals, but significantly more (P<0·0001) patients received angiotensin-converting enzyme inhibitors in hospitals without catheterization laboratories. In contrast, the use of statins and beta-blockers was lower in non-teaching hospitals and in centres without a catheterization laboratory (P<0·0001). The use of antiplatelet agents and anticoagulants was lower in non-teaching hospitals (P<0·0001) but was similar in hospitals with and without a catheterization laboratory.
Pharmacological and interventional therapies were analysed according to four geographical regions (Figs 4 and 5). Australia/New Zealand and Canada were grouped together because they exhibited similar practice patterns. The use of percutaneous coronary intervention and glycoprotein IIb/IIIa inhibitors was considerably higher in the United States compared with other regions. Among those patients receiving glycoprotein IIb/IIIa inhibitors, 66% were used in the setting of percutaneous coronary intervention in the U.S.A., 71% in Australia/ 
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New Zealand and Canada, 80% in Europe, and 56% in Argentina and Brazil. The use of low-molecular-weight heparin was lowest in the United States. Aspirin was used consistently across all four geographical regions. In all geographical locations the majority of patients received antiplatelet or anticoagulant therapy. The use of specific therapies was stratified according to acute coronary syndrome subgroup (Table 2) . Beta-blockers and aspirin were used with remarkably similar frequency, regardless of the underlying cause of the acute coronary syndrome. Calcium-channel blockers were used in a higher proportion of patients with unstable angina (38%) than with non-STEMI (29%) or STEMI (15%).Thrombolytic agents were used in less than half of patients with STEMI and a minority of patients with an initial diagnosis of non-STEMI or unstable angina (5 and 4%, respectively). Lowmolecular-weight heparin was prescribed in all parts of the spectrum of acute coronary syndromes (41% STEMI, 51% non-STEMI, 46% unstable angina). Unfractionated heparin was used more frequently in STEMI (66%) than non-STEMI (61%) patients. Cardiac catheterization was undertaken in half of the patients with STEMI or non-STEMI (55% and 53%, respectively), but was less commonly used in the unstable angina group (42%). Use of percutaneous coronary intervention was also lowest in the unstable angina group (18%) compared with the STEMI (40%) and non-STEMI (28%) groups. Coronary artery bypass grafting was carried out in a minority of patients, but occurred most frequently in those with non-STEMI (10%). Thus the majority of patients with welldefined acute coronary syndromes do not undergo revascularization procedures during hospitalization. The hospital death and reinfarction event rates (Table 3) were higher in patients with myocardial infarction (death 8%, reinfarction 3%) than in patients with unstable angina (death 2%, reinfarction 1%), rule-out myocardial infarction (death 3%, reinfarction 0·2%) or chest pain (death 2%, reinfarction 1%). There was no difference in hospital death and reinfarction rates with respect to hospital type. Other hospital outcomes (Table 3) were not significantly different with respect to hospital type (teaching vs non-teaching, catheterization laboratory vs without catheterization laboratory).
Heterogeneity was observed in the rates of hospital death/reinfarction which varied between geographical regions (Table 4 ). There was no significant difference between regions with respect to other hospital outcomes (Table 4 ).
Discussion
The GRACE study was established to provide insights into contemporary and evolving management and outcome of patients with the full spectrum of acute coronary syndromes. This was achieved using pre-specified criteria for definition, strategies to minimize bias in patient recruitment, and quality control and audit. The study satisfies the quality criteria set out for registries in the recent editorial by Alpert [14] . GRACE provides up-to-date performance data for clusters of hospitals and for individual hospitals using global and practicebased comparators. Thus GRACE provides important insights into the variation in treatment practices in relation to hospital and post-discharge outcomes of patients hospitalized with acute coronary syndromes in various regions throughout the world.
Of the 11 543 patients included, 38% had a final diagnosis of unstable angina, 30% had STEMI, and 25% had non-STEMI. This finding reflects the pattern of acute coronary syndromes reported in other studies such as the ENACT study. That cross-sectional study, carried out in mid 1999, collected data on the number of patients hospitalized with acute coronary syndromes in 390 hospitals in 29 European countries [2] . The investigators found that unstable angina was the most frequent cause of hospitalization (46%), followed by acute myocardial infarction (39%), with the relative prevalence of both being consistent between countries. The ENACT investigators also reported that patients with unstable angina were hospitalized for a median of 8·5 days, with a median length of stay in the coronary or intensive care unit of 3·4 days. These findings relate closely with those in GRACE, in which the median stay was 8 days, with 2 days spent in the coronary care/intensive care unit. In contrast, the median length of stay reported in the PRAIS-UK study was only 5 days [10] . A comparison of results reported in the ENACT study and the GRACE study is given in Table 5 . In the ENACT study, the use of aspirin was slightly higher than that in GRACE, whereas the use of low-molecular-weight heparin was higher in GRACE patients with STEMI than similar patients in ENACT. Glycoprotein IIb/IIIa inhibitors use in unstable angina/NSTEMI patients was much higher in the GRACE study, as was the rate of percutaneous coronary intervention, including that of primary intervention, in STEMI patients.
The results presented in this paper show a striking consistency in the hospital use of aspirin, with over 91% of patients receiving an antiplatelet upon admittance to hospital. This finding is consistent with the rates reported in other observational studies and with current medical practice, where the majority of patients presenting with acute coronary syndromes are given aspirin [2, 10, 11, 15, 22] . The use of antiplatelet agents and anticoagulants showed no variation by hospital type or geographical region. In the EUROASPIRE II study [22] , which surveyed patients with established coronary artery disease from 15 European countries, the use of antiplatelet therapy ranged from 77% in Hungary to 96% in Germany. However, the overall rate was similar to that reported in GRACE, with 90% receiving antiplatelet therapy at discharge.
There was consistency in the use of angiotensinconverting enzyme inhibitors at discharge in both teaching and non-teaching hospitals, but a greater proportion of patients were treated with angiotensin-converting enzyme inhibitors in hospitals without a catheterization laboratory compared with those with a catheterization laboratory. The proportion of patients who received angiotensin-converting enzyme inhibitors at discharge in the GRACE study (55%) was somewhat higher than that reported in EUROASPIRE II (38%) [22] (Table 6 ). In GRACE, only small geographical differences were noted in the use of angiotensin-converting enzyme inhibitors. The use of beta-blockers at discharge ranged from 75% in unstable angina to 81% following STEMI (overall rate 71%), which is somewhat higher than the 66% in EUROASPIRE II [22] ( Table 6 ). The use of beta-blockers was also significantly higher in patients discharged from teaching hospitals and sites with access to cardiac catheterization facilities when compared with non-teaching hospitals and those without cardiac catheterization facilities.
There was marked variation in the use of statins at discharge, with higher use being noted in teaching than non-teaching hospitals (51% vs 37%) and in those with catheterization laboratories (47% vs 43%). The overall rate of statin use at discharge was 47%, which is slightly higher than that reported in the EUROASPIRE II study (43%) [22] (Table 6 ). There were geographical variations in the use of statins at discharge, which ranged from 26 to 57%. This variation in use may be related to current uncertainty about the early use of statins following a cardiac event (although their use in long-term secondary prevention is well established), or it may be related to other factors including cost [7] . 
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There was marked hospital variation in the rate of percutaneous coronary intervention and glycoprotein IIb/IIIa inhibitor use, with higher use being noted in teaching hospitals and hospitals with catheterization laboratories, and also in hospitals in the United States. The higher use of percutaneous coronary intervention in such hospitals reflects the more specialist skills needed to perform this procedure and the availability of appropriate equipment. The wide geographical variation in the use of percutaneous coronary intervention has been documented previously [16] . In particular, the higher use of percutaneous coronary intervention at sites in the United States is likely to be because the majority of US hospitals participating in GRACE have catheterization laboratories [16] [17] [18] . The use of glycoprotein IIb/IIIa inhibitors was relatively low in non-teaching hospitals (11%) and in hospitals without a catheterization laboratory (4%) in the GRACE study, but the use was higher in teaching hospitals (19%) and in hospitals with a catheterization laboratory (20%). This is probably because this therapy is most clearly established in percutaneous coronary intervention and has yet to be adopted in non-teaching and less specialized hospitals [3, 13] . For example, in nonteaching hospitals, 262 patients received glycoprotein IIb/IIIa inhibitors in the setting of percutaneous coronary intervention and 165 patients received glycoprotein IIb/IIIa inhibitors without percutaneous coronary intervention. The corresponding figures for teaching and less specialized hospitals were 902 and 339, respectively. The use of glycoprotein IIb/IIIa inhibitors was highest in the United States, but even here it was only used in less than a third of all patients. The use of these agents has been shown in several clinical trials to reduce adverse outcome, in particular, frequency of non-fatal myocardial infarction. As a result its use is predicted to increase in the future [19] . Low-molecular-weight heparins were used more frequently in non-teaching hospitals and in those without a catheterization laboratory, and in European and Australian/New Zealand/Canadian sites. This pattern may change as data emerge for the use of low-molecular-weight heparins with percutaneous coronary intervention and with glycoprotein IIb/IIIa inhibitors [20, 21] . The geographical variation seen in GRACE for some treatments has also been observed in other studies. The ESSENCE study observed considerable differences between countries in the use of drug therapies, [12] with patients in centres located in Argentina receiving the highest percentage of nitrates and beta-blockers and the lowest percentage of calcium channel blockers. Conversely, patients in the U.K. received the lowest percentage of nitrates and beta-blockers and the highest percentage of calcium channel blockers. Similar results were reported for beta-blockers in the present study, with the highest use being reported in the United States and at sites in Argentina/Brazil and the lowest rates reported for Europe and Australia/New Zealand/ Canada. By contrast, calcium-channel blockers were given more frequently to patients in the United States and Australia/New Zealand/Canada, when compared with patients in Europe and sites in Argentina/Brazil. Use of these agents was also higher in teaching than non-teaching hospitals and at sites with access to cardiac catheterization facilities when compared to those without. At discharge, the highest rate of prescription of calcium-channel blockers was in the United States. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) study, which was limited to patients without ST-segment elevation myocardial infarction, also observed wide variation in management practices by country, in particular in the use of invasive cardiac procedures [16] , with the United States and Brazil having the highest rates for these procedures. However, in the OASIS study this observation did not translate into reductions in mortality.
Analysis of the use of different therapies by underlying condition (STEMI, non-STEMI and unstable angina) again showed a consistent use of aspirin in all three groups, in line with management guidelines on the use of aspirin in patients with unstable angina [9] and myocardial infarction [8] . The use of beta-blockers was also remarkably consistent and reflects the current literature, which advocates the use of beta-blockers, particularly in patients with unstable angina [11, 23] . Thrombolytic agents were used primarily in patients with STEMI, again reflecting the published literature [2, 7] . While 5% of patients who initially present with non-STEMI also received thrombolytics, this likely reflects subsequent development of ST elevation during the hospital course. The use of low-molecular-weight heparin was highest in the non-STEMI group, in line with recommendations for this indication [9] , but it is interesting to note that the use of unfractionated heparin was higher in all three groups compared with lowmolecular-weight heparin despite the fact that two studies have shown that enoxaparin is superior to unfractionated heparin in the reduction of ischemic clinical events [24, 25] .
Cardiac catheterization was performed less frequently in the unstable angina group (42%) compared with the STEMI (55%) and non-STEMI (53%) groups, and percutaneous coronary intervention was used less frequently in those with unstable angina. It is interesting to note that the use of percutaneous coronary intervention was around 34% in patients with myocardial infarction, which is considerably higher than the rate of 8% seen in the European ENACT study (April-June 1999) [2] . Coronary artery bypass grafting was carried out in a small number of patients, but was performed most frequently in those with non-STEMI.
The hospital death rate for patients with STEMI in the GRACE study was 7%, which is slightly less than that reported in the NRMI 3 study of AMI patients (9%) [26] . The NRMI 1, 2 and 3 studies have demonstrated a steady decline in the hospital mortality rate over the period 1990 to 1999. The findings from this report, which covers the period April 1999 to December 2000, lend further support to the declining hospital mortality rate for these patients. In the GRACE study, no differences in hospital death rate was observed with respect to hospital type. This contrasts with the NRMI 2 study, in which significant differences were reported depending on the type of facilities available (13·4-15·7%); despite these variations, equally good outcomes were found at 90 days for both community and tertiary care hospitals [27] . In the OASIS registry of patients with non-STEMI and unstable angina, the rate of death at 7 days was 5% [28] , which compares to a hospital death rate of 6% in patients with non-STEMI and 3% for unstable angina in the GRACE study. No geographical differences were apparent in hospital outcomes in the OASIS registry. In the GRACE study, important geographical variations were apparent with respect to hospital outcomes including death/reinfarction and renal failure. However, these findings must be interpreted with caution given the limitations of the study and the difficulties with adjusting for baseline differences between populations.
Study limitations
The methods by which data were collected for the GRACE registry are subject to a number of recognized limitations that may limit the ability to generalize the study findings. The relatively low in-hospital mortality rates described in some countries must be interpreted with caution given the fact that, in some of the clusters using warm pursuit, the requirement by Internal Review Boards for patient consent may have resulted in the exclusion of dying patients from the registry. In addition, restriction of the registry to patients who are admitted may have resulted in the exclusion of patients dying early in the emergency room. The participating clusters may reflect regional practices and outcomes, but not necessarily those of the entire country. Some important geographical regions such as Asia and Africa
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are not represented. Finally, identification of cases is heterogeneous, using 'warm pursuit' in some centres and 'cold pursuit' in others.
Conclusions
These results from GRACE demonstrate differences in the management of patients with STEMI, non-STEMI, and unstable angina, based on hospital type and geographical location. The impact of these differences on subsequent survival will be the subject of further studies using the data from GRACE. Given the significant pressures on health-care systems to practice evidencebased medicine in a cost-effective manner, and the rapid development of treatment strategies for acute coronary syndromes, the results of GRACE provide a reference standard for the uptake of therapies of proven efficacy.
